These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 12208136)
1. Comparison of epidermal keratinocytes and dermal fibroblasts as potential target cells for somatic gene therapy of phenylketonuria. Christensen R; Güttler F; Jensen TG Mol Genet Metab; 2002 Aug; 76(4):313-8. PubMed ID: 12208136 [TBL] [Abstract][Full Text] [Related]
2. Development of a skin-based metabolic sink for phenylalanine by overexpression of phenylalanine hydroxylase and GTP cyclohydrolase in primary human keratinocytes. Christensen R; Kolvraa S; Blaese RM; Jensen TG Gene Ther; 2000 Dec; 7(23):1971-8. PubMed ID: 11175307 [TBL] [Abstract][Full Text] [Related]
3. Characterization of transgenic mice with the expression of phenylalanine hydroxylase and GTP cyclohydrolase I in the skin. Christensen R; Alhonen L; Wahlfors J; Jakobsen M; Jensen TG Exp Dermatol; 2005 Jul; 14(7):535-42. PubMed ID: 15946242 [TBL] [Abstract][Full Text] [Related]
4. Manipulation of the phenylalanine metabolism in human keratinocytes by retroviral mediated gene transfer. Christensen R; Kolvraa S; Jensen TG Cells Tissues Organs; 2005; 179(4):170-8. PubMed ID: 16046863 [TBL] [Abstract][Full Text] [Related]
5. Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system. Ding Z; Harding CO; Rebuffat A; Elzaouk L; Wolff JA; Thöny B Mol Ther; 2008 Apr; 16(4):673-81. PubMed ID: 18362925 [TBL] [Abstract][Full Text] [Related]
6. Expression of phenylalanine hydroxylase (PAH) in erythrogenic bone marrow does not correct hyperphenylalaninemia in Pah(enu2) mice. Harding CO; Neff M; Jones K; Wild K; Wolff JA J Gene Med; 2003 Nov; 5(11):984-93. PubMed ID: 14601136 [TBL] [Abstract][Full Text] [Related]
8. Long-term enzymatic and phenotypic correction in the phenylketonuria mouse model by adeno-associated virus vector-mediated gene transfer. Oh HJ; Park ES; Kang S; Jo I; Jung SC Pediatr Res; 2004 Aug; 56(2):278-84. PubMed ID: 15181195 [TBL] [Abstract][Full Text] [Related]
9. Reversal of metabolic and neurological symptoms of phenylketonuric mice treated with a PAH containing helper-dependent adenoviral vector. Cerreto M; Mehdawy B; Ombrone D; Nisticò R; Ruoppolo M; Usiello A; Daniele A; Pastore L; Salvatore F Curr Gene Ther; 2012 Feb; 12(1):48-56. PubMed ID: 22348550 [TBL] [Abstract][Full Text] [Related]
10. Metabolic basis of sexual dimorphism in PKU mice after genome-targeted PAH gene therapy. Chen L; Thung SN; Woo SL Mol Ther; 2007 Jun; 15(6):1079-85. PubMed ID: 17406346 [TBL] [Abstract][Full Text] [Related]
11. The interplay between genotype, metabolic state and cofactor treatment governs phenylalanine hydroxylase function and drug response. Staudigl M; Gersting SW; Danecka MK; Messing DD; Woidy M; Pinkas D; Kemter KF; Blau N; Muntau AC Hum Mol Genet; 2011 Jul; 20(13):2628-41. PubMed ID: 21527427 [TBL] [Abstract][Full Text] [Related]
12. Complete restoration of phenylalanine oxidation in phenylketonuria mouse by a self-complementary adeno-associated virus vector. Yagi H; Ogura T; Mizukami H; Urabe M; Hamada H; Yoshikawa H; Ozawa K; Kume A J Gene Med; 2011 Feb; 13(2):114-22. PubMed ID: 21322099 [TBL] [Abstract][Full Text] [Related]
14. Reversal of gene expression profile in the phenylketonuria mouse model after adeno-associated virus vector-mediated gene therapy. Oh HJ; Lee H; Park JW; Rhee H; Koo SK; Kang S; Jo I; Jung SC Mol Genet Metab; 2005 Dec; 86 Suppl 1():S124-32. PubMed ID: 16150627 [TBL] [Abstract][Full Text] [Related]
15. Expression of human phenylalanine hydroxylase activity in T lymphocytes of classical phenylketonuria children by retroviral-mediated gene transfer. Lin CM; Tan Y; Lee YM; Chang CC; Hsiao KJ J Inherit Metab Dis; 1997 Nov; 20(6):742-54. PubMed ID: 9427141 [TBL] [Abstract][Full Text] [Related]
16. A novel Pah-exon1 deleted murine model of phenylalanine hydroxylase (PAH) deficiency. Richards DY; Winn SR; Dudley S; Fedorov L; Rimann N; Thöny B; Harding CO Mol Genet Metab; 2020 Nov; 131(3):306-315. PubMed ID: 33051130 [TBL] [Abstract][Full Text] [Related]
17. The fate of intravenously administered tetrahydrobiopterin and its implications for heterologous gene therapy of phenylketonuria. Harding CO; Neff M; Wild K; Jones K; Elzaouk L; Thöny B; Milstien S Mol Genet Metab; 2004 Jan; 81(1):52-7. PubMed ID: 14728991 [TBL] [Abstract][Full Text] [Related]
18. Hepatocytes from wild-type or heterozygous donors are equally effective in achieving successful therapeutic liver repopulation in murine phenylketonuria (PKU). Hamman KJ; Winn SR; Harding CO Mol Genet Metab; 2011 Nov; 104(3):235-40. PubMed ID: 21917493 [TBL] [Abstract][Full Text] [Related]
19. Comparison of adeno-associated virus pseudotype 1, 2, and 8 vectors administered by intramuscular injection in the treatment of murine phenylketonuria. Rebuffat A; Harding CO; Ding Z; Thöny B Hum Gene Ther; 2010 Apr; 21(4):463-77. PubMed ID: 19916803 [TBL] [Abstract][Full Text] [Related]